This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 17-23 March 2024 and includes updates on SARS-CoV-2 variant classification, hepatitis A, pertussis, invasive Group A streptococcal infection, chikungunya, dengue, poliomyelitis, western equine encephalitis and cholera.
This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 17-23 December 2023 and includes updates on cholera, SARS-CoV-2 variant classification, avian influenza in fur farms, hepatitis A, pertussis, a cluster of extensively drug-resistant Shigella Sonnei among men who have sex with men, and an overview of respiratory virus epidemiology in the EU/EE.
In 2022, the first and second most reported zoonoses in humans were campylobacteriosis and salmonellosis, respectively. The number of cases of campylobacteriosis and salmonellosis remained stable in comparison with 2021.
Campylobacteriosis and salmonellosis were the most frequently reported zoonotic diseases in humans in the EU in 2022. For West Nile virus, an increase of the number of infections was observed.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 10-16 September 2023 and includes updates on COVID-19, diphtheria, West Nile virus, avian influenza, dengue, legionnaires' disease, the Rugby World Cup 2023, cutaneous Anthrax, pertussis, botulism and severe floods.
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis B. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis B.